Results 251 to 260 of about 284,082 (261)

Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer

Annals of Oncology, 2008
Kenneth J O'Byrne, R Kolb, K J O'Byrne
exaly  

Cisplatin Nephrotoxicity: A Review

American Journal of the Medical Sciences, 2007
Kenneth Nugent
exaly  

A phase II multicentre study of irinotecan (CPT 11) in combination with cisplatin (CDDP) in metastatic or locally advanced penile carcinoma (EORTC PROTOCOL 30992)

Annals of Oncology, 2008
L Collette, C Theodore, J M Kerst
exaly  

Mechanisms of Cisplatin Nephrotoxicity

Toxins, 2010
William Reeves, Ganesan Ramesh, Ronald Miller   +2 more
exaly  

A phase III trial comparing oral S-1/cisplatin and intravenous 5-fluorouracil/cisplatin in patients with untreated diffuse gastric cancer

Annals of Oncology, 2017
Igor N. Bondarenko, Jaime Feliu, Y Shparyk   +2 more
exaly  

Liposomal cisplatin combined with paclitaxel versus cisplatin and paclitaxel in non-small-cell lung cancer: a randomized phase III multicenter trial

Annals of Oncology, 2010
George P Stathopoulos
exaly  

Comparison of two different S-1 plus cisplatin dosing schedules as first-line chemotherapy for metastatic and/or recurrent gastric cancer: a multicenter, randomized phase III trial (SOS)

Annals of Oncology, 2015
Yoon-Koo Kang, S-H Cho, S R Park
exaly  

Phytochemicals: Current strategy to sensitize cancer cells to cisplatin

Biomedicine and Pharmacotherapy, 2019
Guangjuan Zheng, Chao-Yue Sun, Bing Feng
exaly  

Combination gemcitabine and cisplatin chemotherapy for metastatic or recurrent nasopharyngeal carcinoma: report of a phase II study

Annals of Oncology, 2002
Wai-Hon Lau, H H Y Yiu, W Foo
exaly  

Cisplatin binding to proteins: A structural perspective

Coordination Chemistry Reviews, 2016
Antonello Merlino, Luigi Messori
exaly